Medical Affairs Excellence

Structuring, Funding, & Aligning for Global Success

Publication Date	May 2004
Publisher	Best Practices
Product Type	Report
Pages	56
ISBN Number	not applicable
Product Code	BPC00001

Price

£2,530.00
approximately: $4,727 | €3,209

PDF

PRINT £2,530 ($4,727 | €3,209)

Order above formats by FAX

Summary

In today's challenging healthcare environment, medical affairs' role has become even more crucial to pharmaceutical companies' success. Confronted with declining R&D productivity, escalating development costs, increasing competition, growing price pressures and intensified regulatory and public scrutiny, pharmaceutical companies seek to maintain double-digit revenue and earnings growth demanded by investors. In addition, companies are reallocating resources in response to Office of Inspector General (OIG) guidelines. This study uncovers how leading companies are working to align, staff and fund medical affairs capabilities to respond to these challenges.

Content

Executive Summary
Measuring Performance
- Medical Affairs Performance Measures
- Overall Medical Affairs Staffing Levels
- Staffing by Capabilities
- Imputed FTEs Per Dedicated MA Capability
- FTEs to # of Compounds
- FTEs to # of Therapy Areas
- FTEs to U.S. Sales
- Staffing Changes and Drivers
- Outsourcing: Company
- Outsourcing: Capability
- External Spend Average and Range
- External Spend: Average By Capability
- External Spend Per Compound
- Source and Distribution of Spend
- Factors Driving High Resource Consumption
Staffing and Spend
- Introduction
- Mission, Roles, & Responsibilities
- Geographic Span of Responsibility
- Product Lifecycle Span of Responsibility
- Functional Components and Structure
- Cross-Functional Interfaces
Organizational Structures and Processes
Appendix
- Glossary of Terms